| scholarly article | Q13442814 |
| P50 | author | Jens Juul Holst | Q28373106 |
| Sten Madsbad | Q39034312 | ||
| Jan Erik Henriksen | Q39438302 | ||
| Benjamin A. H. Jensen | Q40143669 | ||
| P2093 | author name string | A Vølund | |
| K Aaboe | |||
| T Krarup | |||
| P2860 | cites work | Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 |
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 | ||
| Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? | Q33803409 | ||
| Report of the expert committee on the diagnosis and classification of diabetes mellitus | Q34167177 | ||
| Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine | Q34180164 | ||
| Accurate assessment of beta-cell function: the hyperbolic correction | Q34508795 | ||
| The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 | ||
| Nutrient, neural and endocrine control of glucagon-like peptide secretion | Q36012464 | ||
| Glucagon-like peptide-1, glucose homeostasis and diabetes | Q37114343 | ||
| Immunoassays for the incretin hormones GIP and GLP-1. | Q37595932 | ||
| Banting lecture 1990. Beta-cells in type II diabetes mellitus | Q37633379 | ||
| Effects of glucocorticoids on carbohydrate metabolism | Q39631347 | ||
| Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects* | Q40329405 | ||
| Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus | Q40337480 | ||
| The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects | Q42436041 | ||
| Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans | Q42512452 | ||
| Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients | Q44110180 | ||
| Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test | Q44251909 | ||
| beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 | ||
| Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes | Q45112803 | ||
| Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes | Q46739343 | ||
| Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients | Q46830628 | ||
| Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance | Q46944971 | ||
| Critical evaluation of the 'heated-hand-technique' for obtaining 'arterialized' venous blood: incomplete arterialization and alterations in glucagon responses | Q48757055 | ||
| Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. | Q51387579 | ||
| Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. | Q51561183 | ||
| Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. | Q51571637 | ||
| Proinsulin as a marker for the development of NIDDM in Japanese-American men. | Q51590740 | ||
| Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. | Q51598262 | ||
| Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. | Q51598705 | ||
| Effect of hypercorticism on regulation of skeletal muscle glycogen metabolism by epinephrine | Q51606171 | ||
| Validation of methods for measurement of insulin secretion in humans in vivo. | Q52077029 | ||
| Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. | Q54148814 | ||
| Mechanisms of dexamethasone-induced insulin resistance in healthy humans. | Q54193481 | ||
| Reduced Incretin Effect in Type 2 Diabetes | Q58168459 | ||
| Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus | Q58168509 | ||
| Evaluation of beta-cell secretory capacity using glucagon-like peptide 1 | Q58169163 | ||
| Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics* | Q58169791 | ||
| The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera | Q58449428 | ||
| Glucagon-related peptides in the human gastrointestinal mucosa | Q58449435 | ||
| Circulating glucagon after total pancreatectomy in man | Q58449447 | ||
| Hyperproinsulinemia in type II diabetes | Q68032837 | ||
| Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 | ||
| Basal and stimulated hyperinsulinism: reversible metabolic sequelae of obesity | Q69743827 | ||
| Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses | Q93538767 | ||
| P433 | issue | 5 | |
| P921 | main subject | insulin resistance | Q1053470 |
| type 2 diabetes | Q3025883 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1406-1416 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. | |
| P478 | volume | 55 |
| Q40046197 | A Randomized Placebo-Controlled Trial of Prophylactic Dexamethasone for Transcatheter Arterial Chemoembolization. |
| Q38806056 | Altered expression of uncoupling protein 2 in GLP-1-producing cells after chronic high glucose exposure: implications for the pathogenesis of diabetes mellitus. |
| Q35387387 | Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort study |
| Q37106376 | Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. |
| Q58801848 | Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role? |
| Q48231744 | Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass |
| Q26741374 | Impact of Glucocorticoid Excess on Glucose Tolerance: Clinical and Preclinical Evidence |
| Q33754087 | Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective study |
| Q38038655 | Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia |
| Q38091130 | Influence of glucocorticoids and growth hormone on insulin sensitivity in humans |
| Q42241562 | Normal physical activity obliterates the deleterious effects of a high-caloric intake |
| Q35140228 | Pancreatic alpha-cell dysfunction contributes to the disruption of glucose homeostasis and compensatory insulin hypersecretion in glucocorticoid-treated rats. |
| Q58167429 | Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance |
| Q54457110 | Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. |
| Q42620094 | The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring |
| Q48278731 | The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers |
| Q36281505 | The incretin effect in critically ill patients: a case-control study |
| Q38733474 | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions |
| Q36902183 | The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? |
| Q47886547 | Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers |
| Q41510683 | Voluntary exercise improves metabolic profile in high-fat fed glucocorticoid-treated rats |
| Q37412811 | What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters |
Search more.